In a recent interview with the Handelsblatt newspaper, the Chief Financial Officer of Siemens AG, Ralf Thomas, disclosed that the company is reevaluating its majority stake in medical technology subsidiary Siemens Healthineers. The German technology group is considering the economic opportunities in the healthcare sector and the potential impact of retaining its 75% equity stake in Healthineers, which is currently valued at 45 billion euros ($46.91 billion).
Thomas highlighted that the synergies between Siemens AG and Healthineers may not be sufficient to justify the significant capital commitment. As a result, the company is reviewing its investment in the subsidiary and will present its findings at a capital markets day at the end of 2025.
Siemens AG had previously spun off Healthineers in 2018 and maintained its majority stake. However, Thomas hinted at the possibility of selling around 5% of the stake to fund the acquisition of U.S. software company Altair. Despite the potential divestment in Healthineers, Thomas affirmed the company’s commitment to its Mobility train division, which has faced calls from investors for a spin-off.
In his statement to Handelsblatt, Thomas expressed confidence in the current state of the Mobility division and emphasized that there is no immediate need to part ways with it. The CFO’s strategic considerations reflect Siemens AG’s ongoing assessment of its investments and business portfolio.
($1 = 0.9592 euros)